Genmab’s Buy Rating Affirmed by Promising Epcoritamab Trials and Regulatory Milestones

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Genmab (GMAB – Research Report), retaining the price target of $50.00.

Ram Selvaraju has given his Buy rating due to a combination of factors involving Genmab’s promising clinical data and the anticipation of regulatory milestones. The upcoming European Hematology Association (EHA) meeting is expected to showcase eight datasets for epcoritamab, which demonstrate its potential efficacy across various indications like Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). This comprehensive data presentation could offer detailed insights into epcoritamab’s treatment efficacy, further solidifying its therapeutic profile.
Additionally, key results from the EPCORE NHL-1 trial were presented at ASH 2023, revealing an impressive Overall Response Rate (ORR) and Complete Response (CR) rate for epcoritamab in treating follicular lymphoma. The Breakthrough Therapy Designation (BTD) granted by the FDA for epcoritamab in refractory FL after two or more lines of systemic therapy, and the EMA’s commencement of a scientific review, underscore the drug’s potential and pave the way for accelerated approval processes. These developments, combined with the anticipation of an FDA decision, contribute to Selvaraju’s optimistic Buy rating for Genmab’s stock.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Genmab (GMAB) Company Description:

Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.